2 October 2024 - As part of the continued implementation of the Biden-Harris Administration’s historic prescription drug law, the Inflation Reduction Act, the US Department of Health and Human Services, through the Centers for Medicare & Medicaid Services (CMS), released final guidance today outlining the process for the second cycle of negotiations under the Medicare Drug Price Negotiation Program. 

The guidance also explains how CMS will help ensure people with Medicare can access drugs at the negotiated prices from the first and second cycles when those prices become effective beginning in 2026 and 2027, respectively.

Read CMS press release